Immunoconjugate
{{Short description|Combinations of diagnostic or therapeutic substances linked with specific immune substances}}
Immunoconjugates are antibodies conjugated (joined) to a second molecule, usually a toxin, radioisotope or label.{{cite journal |vauthors=Goldenberg DM, Sharkey RM |title=Novel radiolabeled antibody conjugates |journal=Oncogene |volume=26 |issue=25 |pages=3734–44 |year=2007 |pmid=17530026 |doi=10.1038/sj.onc.1210373|url=https://zenodo.org/record/895520 |doi-access=free }}
These conjugates are used in immunotherapy{{Citation needed|date=October 2010}} and to develop monoclonal antibody therapy as a targeted form of chemotherapy{{cite journal |vauthors=Khandare JJ, Minko T |title=Antibodies and peptides in cancer therapy |journal=Critical Reviews in Therapeutic Drug Carrier Systems |volume=23 |issue=5 |pages=401–35 |year=2006 |pmid=17425513|doi=10.1615/CritRevTherDrugCarrierSyst.v23.i5.20 }} when they are often known as antibody-drug conjugates.
When the conjugates include a radioisotope see radioimmunotherapy.
When the conjugates include a toxin see immunotoxin.
References
{{reflist}}
Further reading
- [http://www.nature.com/nrclinonc/journal/v4/n4/full/ncponc0774.html Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. 2007] looks useful from the abstract.
- [http://onlinelibrary.wiley.com/doi/10.3322/canjclin.56.4.226/pdf Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. 2006] full article, 18 pages.
- [http://journals2005.pasteur.ac.ir/NB/23%289%29/1137%20-%201146.pdf Arming antibodies: prospects and challenges for immunoconjugates. 2005] 10 pages.
{{Immunology-stub}}